The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIV.a

Angioedema (may cause UAO, asphyxia and death)

Publications

Mackenzie M, Wood LA

Lingual angioedema associated with everolimus.

Acta oncologica (Stockholm, Sweden) 2010;49;107-9 — 2010 — 107-9

Er F, Nia AM, Erdmann E

[67-year-old patient with speech disorder and dysphagia].

Deutsche medizinische Wochenschrift (1946) 2008 Nov;133;2463-4 — 2008 Nov — 2463-4

Rothenburger M, Zuckermann A, Bara C, Hummel M, Strüber M, Hirt S, Lehmkuhl H,

Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2007 Apr;26;305-11 — 2007 Apr — 305-11

Fuchs U, Zittermann A, Berthold HK, Tenderich G, Deyerling KW, Minami K, Koerfer R

Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema.

Transplantation 2005 Apr 27;79;981-3 — 2005 Apr 27 — 981-3